It is also proposed that Tα1’s anti-tumor efficacy can be restored by blocking the MyD88 signaling pathway, raising the possibility that future research may examine ways to mitigate Tα1’s adverse effects when used to treat LC. This evidence concerns the gene MYD88 and laryngotracheoesophageal cleft.